The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
+ IV infusions every 12 weeks Current regimen requires clinic visits; Lilly is developing a single sub-cutaneous co-formulation with tirzepatide to match pen-style convenience and possibly add further fat-loss potency with the dual GIP-GLP1 agonism.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.